Iowanews Headlines

Hyperparathyroidism market

The Hypoparathyroidism market across the seven major markets (7MM), the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan — is anticipated to witness steady growth over the coming decade. Valued modestly in 2025, the market is projected to reach USD 1,650 million by 2034, expanding at a CAGR of 1.2% during the forecast period.

The United States is expected to remain the dominant contributor, holding the largest market share throughout the forecast period. Meanwhile, the EU4 and the UK collectively represent a significant portion of the patient population, with Japan contributing notably to the overall market landscape.

Despite the availability of conventional therapies such as calcium supplements, vitamin D analogs, and recombinant parathyroid hormone (PTH) analogs, treatment gaps persist due to limited efficacy in fully restoring calcium-phosphate balance and reducing long-term complications.

The future of the Hypoparathyroidism market looks promising with several key players — including Vidasym Inc., Mitsubishi Tanabe Pharma, Shanghai Hengrui Pharmaceutical, and others — actively advancing their therapeutic candidates through clinical development. The ongoing innovation in PTH replacement therapies and next-generation biologics is expected to enhance disease management and patient outcomes.

Overall, the Hypoparathyroidism market is poised for consistent, sustainable growth through 2034, supported by a growing focus on precision therapies, improved disease understanding, and continued clinical research efforts.

DelveInsight’s report, “Hyperparathyroidism Market Insights, Epidemiology, and Market Forecast-2034” provides a comprehensive analysis of the Hyperparathyroidism landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Hyperparathyroidism market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

Some of the key facts of the Hyperparathyroidism Market Report:

• The leading Hyperparathyroidism Companies developing therapies include Vidasym Inc., Mitsubishi Tanabe Pharma, Shanghai Hengrui Pharmaceutical, and others.

• Potential future therapies for Hyperparathyroidism include PARSABIV (Etelcalcetide), UPASITA (Upacicalcet), and others.

• The future of Hyperparathyroidism treatment holds promise, driven by ongoing research and the development of innovative therapies. Current management strategies, such as symptomatic medications, physical therapy, and supportive care, remain essential.

Hyperparathyroidism Overview

Hyperparathyroidism is a disorder in which the parathyroid glands—small glands located near the thyroid in the neck—produce an excessive amount of parathyroid hormone (PTH). This hormonal imbalance results in hypercalcemia, or abnormally high calcium levels in the blood, which can lead to a variety of health complications. The condition is categorized into three main types, each driven by distinct underlying mechanisms.

• Primary Hyperparathyroidism: Occurs when one or more parathyroid glands become enlarged and secrete excessive PTH, leading to elevated calcium levels due to increased calcitriol production and calcium release from the bones.

• Secondary Hyperparathyroidism: Develops when persistently low levels of calcium or vitamin D—often caused by nutritional deficiencies—stimulate the parathyroid glands to overproduce PTH in an attempt to restore calcium balance by mobilizing calcium from bone tissue.

• Tertiary Hyperparathyroidism: Typically arises in individuals with long-term calcium or vitamin D deficiency, or impaired calcitriol synthesis resulting from chronic kidney disease. Over time, all four parathyroid glands may become enlarged and continue to produce excess PTH even when calcium levels normalize, leading to sustained hypercalcemia.

Learn more about Hyperparathyroidism treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Hyperparathyroidism Treatment Market

Key Factors Driving Growth in the Hyperparathyroidism Market

• Rising Hyperparathyroidism Burden in the Aging Population

The global Hyperparathyroidism market continues to expand, driven primarily by the rising disease burden among the aging population. In 2024, the United States recorded approximately 2.6 million diagnosed prevalent cases of hyperparathyroidism, with individuals aged 60 years and above representing the largest affected group. Primary Hyperparathyroidism (PHPT) accounted for nearly 60% of all cases, underscoring its clinical dominance. The growing prevalence reflects not only an aging demographic but also advancements in diagnostic technologies that have improved disease detection and classification.

• Advances in Diagnosis and Treatment Approaches

Significant progress in diagnostic imaging and treatment modalities has transformed disease management across primary, secondary, and tertiary hyperparathyroidism. Treatment strategies range from surgical parathyroidectomy—the only curative option for PHPT—to medical management approaches in SHPT and THPT using phosphate binders, vitamin D analogs, and calcimimetics. Despite the effectiveness of surgery, localization challenges remain, particularly in patients with small adenomas, ectopic glands, or multiglandular disease. The adoption of advanced imaging tools such as sestamibi scans, high-resolution ultrasound, and 4D-CT continues to enhance preoperative precision and patient outcomes.

• Approved Therapies and Emerging Pipeline

The therapeutic landscape has broadened with the introduction of approved therapies such as PARSABIV and RAYALDEE in the United States, and ORKEDIA and UPASITA in Japan for the treatment of secondary hyperparathyroidism. Among these, PARSABIV remains the only therapy approved across the seven major markets (7MM). However, the pipeline for hyperparathyroidism remains limited, with only a few active clinical development programs underway. This gap highlights the unmet need for innovative, long-term, and disease-modifying treatments that can improve patient quality of life and reduce recurrence rates.

As research and clinical advancements continue, the Hyperparathyroidism market is expected to maintain its growth trajectory, driven by improved disease awareness, evolving treatment paradigms, and the emergence of novel therapeutic approaches.

Recent Developments in Hyperparathyroidism Clinical Trials:

• In October 2025, FDA approved OPKO’s Rayaldee (extended-release calcifediol) for treatment of secondary hyperparathyroidism (SHPT) in adults with stage 3–4 CKD who are vitamin-D deficient, a regulatory development with immediate treatment implications for a large CKD population.

• In September 2025, BridgeBio announced that it will present Phase-2 proof-of-concept data for Encaleret in post-surgical hypoparathyroidism, demonstrating continued interest in small-molecule approaches for parathyroid-hormone related disorders and cross-talk between hypoparathyroidism and hyperparathyroidism research communities.

• In September, 2025, Recent corporate filings and investor documents from Hengrui Group reaffirm the company’s continued investments in parathyroid/CKD-related programs. SHR6508 (a calcimimetic developed by Shanghai Hengrui) continues to appear in clinical registries (mass balance and other studies), indicating active development and clinical pharmacology workstreams in late-stage development channels.

• Clinical literature through Sept–Oct 2025 reported improved outcomes with modern medical management of SHPT (notably with newer calcimimetics and extended-release vitamin D analogues) and described improved imaging and perioperative strategies for localizing adenomas in PHPT (4D-CT, fluorocholine PET). These data reinforce a trend toward combining advanced imaging, medical therapy, and patient-level biomarkers in treatment plans.

Learn more about the recent advancements in Hyperparathyroidism treatment landscape @ Hyperparathyroidism Recent Developments

Hyperparathyroidism Epidemiology

• In 2024, the United States reported approximately 2.61 million diagnosed prevalent cases of hyperparathyroidism.

• Individuals aged 60 years and older represented the largest segment of the affected population. Across the seven major markets (7MM), females accounted for nearly 70% of all hyperparathyroidism cases, highlighting a notable gender disparity in disease occurrence.

• In Japan, the diagnosed prevalence of hyperparathyroidism was estimated at around 479,000 cases in 2024.

Hyperparathyroidism Epidemiology Segmentation

• Total Prevalent Cases of Hyperparathyroidism

• Total Diagnosed Prevalence Cases of Hyperparathyroidism

• Type-Specific Cases of Hyperparathyroidism

• Age-specific Cases of Hyperparathyroidism

• Gender-specific Cases of Hyperparathyroidism

• Total Treated cases of Hyperparathyroidism

Hyperparathyroidism Emerging Drugs

• MT1013: Shaanxi Micot Technology Limited Company

• SHR6508: Shanghai Hengrui Pharmaceutical Co., Ltd.

Hyperparathyroidism Market Barriers

Despite advancements in diagnosis and treatment, the Hyperparathyroidism market faces several critical barriers that may hinder growth and therapeutic adoption over the forecast period.

• Limited Disease Awareness and UnderdiagnosisMany cases of hyperparathyroidism, particularly mild or asymptomatic forms, remain undetected due to lack of awareness among patients and delayed screening by healthcare providers. This underdiagnosis reduces early intervention rates and limits the eligible treatment population.

• Diagnostic Complexity and Accessibility ChallengesAccurate localization of hyperfunctioning parathyroid glands often requires advanced imaging techniques such as sestamibi scans, 4D-CT, or PET imaging, which may not be widely accessible or affordable in all regions. Misdiagnosis or delayed diagnosis can lead to inappropriate management.

• Dependence on Surgical InterventionParathyroidectomy remains the only curative treatment for Primary Hyperparathyroidism (PHPT). However, surgical expertise, postoperative risks, and localization difficulties, especially in multiglandular or ectopic cases—pose major barriers to widespread surgical success.

• Limited Availability of Disease-Modifying TherapiesThe therapeutic landscape is dominated by symptom-management drugs, including calcimimetics, phosphate binders, and vitamin D analogs. The absence of curative or disease-modifying pharmacologic options restricts long-term treatment efficacy.

Request a free sample copy or view report summary: Hyperparathyroidism Market Report

Scope of the Hyperparathyroidism Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Hyperparathyroidism Companies: Vidasym Inc., Mitsubishi Tanabe Pharma, Shanghai Hengrui Pharmaceutical, and others

• Key Hyperparathyroidism Therapies: PARSABIV (Etelcalcetide), UPASITA (Upacicalcet), and others

• Hyperparathyroidism Therapeutic Assessment: Hyperparathyroidism current marketed and Hyperparathyroidism emerging therapies

• Hyperparathyroidism Market Dynamics: Hyperparathyroidism market drivers and Hyperparathyroidism market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Hyperparathyroidism Unmet Needs, KOL’s views, Analyst’s views, Hyperparathyroidism Market Access and Reimbursement

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/